DD273980B5 - Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung - Google Patents

Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung Download PDF

Info

Publication number: DD273980B5
Authority: DD; German Democratic Republic
Prior art keywords: insulin; agar; preparation; rectal; insulin preparations
Prior art date: 1988-07-12

Application number

DD31782988A

Other languages

German (de)

English (en)

Other versions

DD273980A1 (de

Inventor

Joachim Dipl-Chem Kossowicz

Elke Dr Med Vet Hacker

Karl Dr Rer Nat Milde

Guenter Prof Dr Sc Nat Loesse

Frank Dipl-Chem Mueller

Original Assignee

Berlin Chemie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-07-12

Filing date

1988-07-12

Publication date

1994-04-14

1988-07-12 Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag

1988-07-12 Priority to DD31782988A priority Critical patent/DD273980B5/de

1989-07-11 Priority to JP1177282A priority patent/JPH0347114A/ja

1989-07-11 Priority to DK341489A priority patent/DK341489A/da

1989-07-12 Priority to DE89112726T priority patent/DE58905768D1/de

1989-07-12 Priority to EP89112726A priority patent/EP0371195B1/de

1989-07-12 Priority to CA000605464A priority patent/CA1332349C/en

1989-07-12 Priority to ES89112726T priority patent/ES2059649T3/es

1989-12-06 Publication of DD273980A1 publication Critical patent/DD273980A1/de

1994-04-14 Publication of DD273980B5 publication Critical patent/DD273980B5/de

Links

238000000034 method Methods 0.000 title claims abstract description 10
238000002360 preparation method Methods 0.000 title claims abstract description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 54
102000004877 Insulin Human genes 0.000 title claims description 27
108090001061 Insulin Proteins 0.000 title claims description 27
229940125396 insulin Drugs 0.000 title claims description 27
239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 8
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 6
239000003242 anti bacterial agent Substances 0.000 claims abstract 2
230000005923 long-lasting effect Effects 0.000 claims abstract 2
239000000829 suppository Substances 0.000 claims description 9
108010039627 Aprotinin Proteins 0.000 claims description 7
238000010521 absorption reaction Methods 0.000 claims description 7
229960004405 aprotinin Drugs 0.000 claims description 7
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 7
229920001817 Agar Polymers 0.000 claims description 6
235000010419 agar Nutrition 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 5
229960000282 metronidazole Drugs 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
-1 spheres Substances 0.000 claims description 4
241000206672 Gelidium Species 0.000 claims description 3
239000002775 capsule Substances 0.000 claims 1
239000000243 solution Substances 0.000 claims 1
239000000725 suspension Substances 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 abstract description 8
102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
229940124532 absorption promoter Drugs 0.000 abstract description 2
238000009472 formulation Methods 0.000 description 5
230000000694 effects Effects 0.000 description 4
229960003136 leucine Drugs 0.000 description 4
CDOCNWRWMUMCLP-UHFFFAOYSA-N 2-(dodecanoylamino)-4-methylpentanoic acid Chemical compound CCCCCCCCCCCC(=O)NC(C(O)=O)CC(C)C CDOCNWRWMUMCLP-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000008272 agar Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000000155 melt Substances 0.000 description 3
239000002511 suppository base Substances 0.000 description 3
241001148471 unidentified anaerobic bacterium Species 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000700112 Chinchilla Species 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Chemical Kinetics & Catalysis (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DD31782988A 1988-07-12 1988-07-12 Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung DD273980B5 (de)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
DD31782988A DD273980B5 (de)	1988-07-12	1988-07-12	Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
JP1177282A JPH0347114A (ja)	1988-07-12	1989-07-11	直腸及び膣適用に適する、生物学的に活性なペプチド薬剤を製造する方法
DK341489A DK341489A (da)	1988-07-12	1989-07-11	Fremgangsmaade til fremstilling af praeparater til anvendelse af biologiske aktive peptider til rektale og vaginale formaal
DE89112726T DE58905768D1 (de)	1988-07-12	1989-07-12	Verfahren zur herstellung von zur rektalen und vaginalen anwendung geeigneten praeparaten biologisch aktiver peptide.
EP89112726A EP0371195B1 (de)	1988-07-12	1989-07-12	Verfahren zur Herstellung von zur rektalen und vaginalen Anwendung geeigneten Präparaten biologisch aktiver Peptide
CA000605464A CA1332349C (en)	1988-07-12	1989-07-12	Process for the production of biologically active peptide preparations suitable for vaginal and rectal administration
ES89112726T ES2059649T3 (es)	1988-07-12	1989-07-12	Procedimiento para la elaboracion de preparados peptidos bioactivos adecuados para su uso por via rectal y vaginal.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DD31782988A DD273980B5 (de)	1988-07-12	1988-07-12	Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung

Publications (2)

Publication Number	Publication Date
DD273980A1 DD273980A1 (de)	1989-12-06
DD273980B5 true DD273980B5 (de)	1994-04-14

Family

ID=5600879

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD31782988A DD273980B5 (de)	1988-07-12	1988-07-12	Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung

Country Status (7)

Country	Link
EP (1)	EP0371195B1 (da)
JP (1)	JPH0347114A (da)
CA (1)	CA1332349C (da)
DD (1)	DD273980B5 (da)
DE (1)	DE58905768D1 (da)
DK (1)	DK341489A (da)
ES (1)	ES2059649T3 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD292382B5 (de) *	1990-03-06	1994-03-24	Berlin Chemie Ag	Verfahren zur herstellung eines parenteral applizierbaren lagerbestaendigen immunstimulierenden praeparats
EP0533938A4 (en) *	1991-02-19	1993-06-16	Tsumura & Co.	Composition for rectal administration of difficultly absorbable peptide
EP0617626A1 (en) *	1991-12-18	1994-10-05	Pfizer Inc.	Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation
US6153592A (en) *	1992-11-09	2000-11-28	Port Systems, Llc	Enhancing the bioavailability of proteolytically labile therapeutic agents
US5916582A (en) *	1996-07-03	1999-06-29	Alza Corporation	Aqueous formulations of peptides
DE19712718C2 (de) *	1997-03-26	1999-09-23	Asta Medica Ag	Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
JP2003103582A (ja) *	2001-09-28	2003-04-09	Mitsubishi Materials Corp	射出成形金型
US8032285B2 (en)	2007-11-30	2011-10-04	Shih-Hsiung Li	Device with memory function for controlling closure of vehicle and method thereof
CN115515559B (zh) *	2019-12-20	2026-03-24	翻译生物公司	信使rna的直肠递送

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD252539A1 (de) *	1986-09-17	1987-12-23	Berlin Chemie Veb	Verfahren zur oralen anwendung biologisch aktiver peptide mit verzoegerter wirkung
DD254881A1 (de) *	1986-10-29	1988-03-16	Univ Dresden Tech	Nicht parenteral anwendbares insulinpraeparat mit verzoegerter wirkung

1988
- 1988-07-12 DD DD31782988A patent/DD273980B5/de not_active IP Right Cessation
1989
- 1989-07-11 DK DK341489A patent/DK341489A/da not_active Application Discontinuation
- 1989-07-11 JP JP1177282A patent/JPH0347114A/ja active Pending
- 1989-07-12 CA CA000605464A patent/CA1332349C/en not_active Expired - Fee Related
- 1989-07-12 ES ES89112726T patent/ES2059649T3/es not_active Expired - Lifetime
- 1989-07-12 EP EP89112726A patent/EP0371195B1/de not_active Expired - Lifetime
- 1989-07-12 DE DE89112726T patent/DE58905768D1/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA1332349C (en)	1994-10-11
DK341489D0 (da)	1989-07-11
DK341489A (da)	1990-01-13
EP0371195A1 (de)	1990-06-06
ES2059649T3 (es)	1994-11-16
DD273980A1 (de)	1989-12-06
JPH0347114A (ja)	1991-02-28
EP0371195B1 (de)	1993-09-29
DE58905768D1 (de)	1993-11-04

Legal Events

Date	Code	Title
1993-04-01	UW	Conversion of economic patent into exclusive patent
1994-03-17	RPI	Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
1994-04-14	B5	Patent specification, 2nd publ. accord. to extension act
1996-09-12	RPI	Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
1996-10-24	RPV	Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act)
1999-02-18	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
AT402259B (de)	1997-03-25	Verfahren zur herstellung eines stabilen pharmazeutischen präparats mit einem gehalt an granulozytkolonie stimulierendem faktor
DE4021517B4 (de)	2009-04-09	Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide
DE3885374T2 (de)	1994-02-24	Stabile wässerige Thrombinlösung.
DE60027272T2 (de)	2007-01-25	Stabile, nichtwässrige, einphasige, biokompatible, viskose Träger und Formulierungen, die diese Träger verwenden
DE60034445T2 (de)	2008-01-03	Gefriergetrocknete hgf-präparationen
DE69829254T2 (de)	2005-08-18	Arzneistoffzubereitung mit kontrollierter Wirkstofffreisetzungsrate
DE69715414T2 (de)	2003-05-15	Stabilisierte pharmazeutische zusammensetzung von bdnf
DE2424169A1 (de)	1974-12-05	Implantationskoerper und verfahren zu seiner herstellung
DD298053A5 (de)	1992-02-06	Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
EP0049469A1 (de)	1982-04-14	Kollagene Wundauflage
DE69819145T2 (de)	2004-08-19	Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
DD273980B5 (de)	1994-04-14	Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
EP0315875A1 (de)	1989-05-17	Verfahren zur Herstellung von bioabbaubaren Mikrokapseln wasserlöslicher Peptide und Proteine sowie nach diesem Verfahren erhaltene Mikrokapseln
DE69122472T2 (de)	1997-04-17	Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten
DE102017106216A1 (de)	2018-09-27	Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
DE19712718A1 (de)	1998-10-01	Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
DD209392A5 (de)	1984-05-09	Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
DE3141498C2 (da)	1991-09-12
DE69426244T2 (de)	2001-03-29	Einen für Tumore cytotoxischen Faktor enthaltende pharmazeutische Zusammensetzung
DE19961141A1 (de)	2001-07-26	Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen
DE3688713T2 (de)	1993-12-16	Verfahren zur Stabilisierung eines Urokinasevorläufers und diesen Vorläufer enthaltendes trockenes Präparat.
DE2528460A1 (de)	1977-01-13	Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE1155134B (de)	1963-10-03	Verfahren zur Herstellung von Blutplasmaersatzmitteln aus Kollagenabbauprodukten
DE3532074A1 (de)	1987-03-12	Resorptionsvermittler fuer biologisch aktive peptide
DE19830914C1 (de)	1999-06-24	Verfahren zur Herstellung einer Proteinlösung